Hematopoietic Stem Cell Transplantation from Haploidentical Donors in Patients with Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
FHRG1005742
What is the goal of the study?
This protocol will investigate the safety and efficacy of a TREO-based conditioning regimen prior to infusion of a haploidentical graft. Haploidentical stem cell transplant (Haplo-HCT) is an alternative hematopoietic stem cell source with the advantages of tolerance of HLA disparity and rapid availability for almost all patients. Treosulfan (TREO, dihydroxybusulfan) is a busulfan (BU) analogue that has several attractive characteristics as compared to BU, including better toxicity profile, less erratic pharmacokinetics and potential for higher antileukemic activity. TREO is appealing as an agent in a regimen that is of less intensity than conventional myeloablative regimens, but that can generate enough antileukemic activity to eradicate residual disease and induce sustained remissions in high-risk patients.
Who can participate in the study?
Please contact the study team listed below to learn more.